Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16203803rdf:typepubmed:Citationlld:pubmed
pubmed-article:16203803lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:16203803lifeskim:mentionsumls-concept:C0006826lld:lifeskim
pubmed-article:16203803lifeskim:mentionsumls-concept:C0011923lld:lifeskim
pubmed-article:16203803lifeskim:mentionsumls-concept:C0012984lld:lifeskim
pubmed-article:16203803lifeskim:mentionsumls-concept:C0521447lld:lifeskim
pubmed-article:16203803lifeskim:mentionsumls-concept:C0520484lld:lifeskim
pubmed-article:16203803lifeskim:mentionsumls-concept:C0392292lld:lifeskim
pubmed-article:16203803pubmed:issue19 Pt 2lld:pubmed
pubmed-article:16203803pubmed:dateCreated2005-10-5lld:pubmed
pubmed-article:16203803pubmed:abstractTextMet, an oncogene product and receptor tyrosine kinase, is a keystone molecule for malignant progression in solid human tumors. We are developing Met-directed imaging and therapeutic agents, including anti-Met monoclonal antibodies (MetSeek). In this study, we compared two antibodies, Met5 and Met3, for nuclear imaging of human and canine Met-expressing tumor xenografts in nude mice.lld:pubmed
pubmed-article:16203803pubmed:languageenglld:pubmed
pubmed-article:16203803pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16203803pubmed:citationSubsetIMlld:pubmed
pubmed-article:16203803pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16203803pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16203803pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16203803pubmed:statusMEDLINElld:pubmed
pubmed-article:16203803pubmed:monthOctlld:pubmed
pubmed-article:16203803pubmed:issn1078-0432lld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:ResauJames...lld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:Vande...lld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:QianChao-NanC...lld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:CaoBrianBlld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:ZhaoPingPlld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:KnudsenBeatri...lld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:WatersDavid...lld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:GrossMilton...lld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:TehBin TBTlld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:ShenShurenSlld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:HayRick VRVlld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:SkinnerR...lld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:SuYanliYlld:pubmed
pubmed-article:16203803pubmed:authorpubmed-author:GustafsonMarg...lld:pubmed
pubmed-article:16203803pubmed:issnTypePrintlld:pubmed
pubmed-article:16203803pubmed:day1lld:pubmed
pubmed-article:16203803pubmed:volume11lld:pubmed
pubmed-article:16203803pubmed:ownerNLMlld:pubmed
pubmed-article:16203803pubmed:authorsCompleteYlld:pubmed
pubmed-article:16203803pubmed:pagination7064s-7069slld:pubmed
pubmed-article:16203803pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:meshHeadingpubmed-meshheading:16203803...lld:pubmed
pubmed-article:16203803pubmed:year2005lld:pubmed
pubmed-article:16203803pubmed:articleTitleNuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek).lld:pubmed
pubmed-article:16203803pubmed:affiliationVan Andel Research Institute, Grand Rapids, Michigan 49503, USA. Rick.Hay@vai.orglld:pubmed
pubmed-article:16203803pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16203803pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:16203803pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16203803lld:pubmed